Theracryf Plc (TCF.L)

GBp 0.24

(4.44%)

Market Cap (In GBp)

5 Million

Revenue (In GBp)

396 Thousand

Net Income (In GBp)

-3.13 Million

Avg. Volume

3.36 Million

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.49-2.0
PE
-0.23
EPS
-0.01
Beta Value
1.424
ISIN
GB00BSVYN304
CUSIP
-
CIK
-
Shares
2129620000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Huw Jones BSc, Ph.D.
Employee Count
-
Website
https://theracryf.com
Ipo Date
2015-10-21
Details
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.